A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R

Inclusion Criteria: * Able to sign Inform Consent Forms before study, and fully understand the study contents, process and potential adverse reactions; * Able to complete the study in compliance with the protocol; * Subjects (including their partners) agreed to adopt effective contraceptive measurements from screening to 6 months after the last administration. Part I Proprietary: * Male and female subjects between 18 and 50 years of age, inclusive; * At least 50 kg for male subjects, 45 kg for female, with a Body Mass Index (BMI) between 18-28 ; * Normal or abnormal but of no clinical significance results for physical examination and vital signs. Part II Proprietary:: * Male and female subjects between 18 and 65 years of age, inclusive; * At least 50 kg for male subjects, 45 kg for female subjects, with a Body Mass Index (BMI) between 18-35 kg/m2, inclusive, BMI = weight (kg) / height 2 (m2); * Any proof of HBV infection more than 6 months (including outpatient/inpatient medical records, HBV DNA, HBsAg test sheets, etc.); or with IgM HBcAb negative and HBsAg positive at screening; * No history of therapy including interferon/nucleoside or analog at screening, or discontinuation for more than 1 year from interferon therapy or more than 6 months from nucleoside analog therapy; * HBV DNA ≥ 2×105 IU/mL for HBeAg-positive patients and HBV DNA ≥ 2×104 IU/mL for HBeAg-negative patients at screening; * Serum ALT lower than 5×upper limit of normal at screening. Exclusion Criteria: * Major trauma or surgery within 3 months before screening; * History of treatment that may interfere with drug absorption (e.g, subtotal gastrectomy); * Blood donation or massive blood loss (\> 450 mL) within 3 months prior to screening; * Any history of allergy suspected to be due to any component of the study drug, or allergic constitution (allergy to multiple drug and food); * A history of narcotic drugs intake or alcohol abuse ; * Acute infection within 2 weeks before screening; * Suffering from serious diseases of the circulatory, respiratory, urinary, vascular, endocrine, immune, mental and nervous systems; * History of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, heart failure of grade III or IV, or stroke within 6 months prior to screening; * Patients with existing malignant tumors (except for skin non-melanoma, cervical intraepithelial neoplasia, thyroid tumor, breast tumor, etc. after treatment with no signs of recurrence); * Any surgery or hospitalization anticipated during the study; * Treatment history of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before study administration; * Medication history of definitely strong CYP3A4 inhibitors or inducers within 2 weeks before screening; * Involved in any other study drug administration or clinical study of medical devices within 1 month before screening; Involved in any clinical study of HBV virus nucleocapsid inhibitors in the past; * Any abnormality of electrocardiogram not suitable for the study judged by physician; * Positive pregnancy test results or subject is lactating for female subjects; * Positive test results of HCV-Ab, HCV core antigen and HCV RNA (PCR); or HIV antibody; or Treponema pallidum antibody further confirmed by rapid plasma reagin (RPR) test; * Consumption of chocolate or any diets containing caffeine or rich in xanthine, or any alcohol-containing products within 48 h before the initial administration; * Positive results of drug abuse tests (morphine, marijuana) or alcohol breath tests; * Other conditions in which subjects are not suitable for the study in the opinion of investigators. Part I Proprietary: * More than 5 cigarettes everyday within 1 month before the study; * Intake of any prescription or over-the-counter (OTC) drugs, vitamin, herbs, other inappropriate diet or supplements in opinion of investigators within 7 days before screening; * Positive HBsAg test results; * Any clinically significant abnormalities in laboratory tests. Part II Proprietary : * Estimated glomerular filtration rate (eGFR) ˂ 60 mL/min/1.73 m2 based on serum creatinine and formula for modification of diet in renal disease (MDRD) based on values at screening; * Patients with clinically significant acute or chronic liver disease not caused by HBV infection (including but not limited to alcoholic liver disease, severe or higher non-alcoholic fatty liver disease, autoimmune liver disease, Gilbert syndrome or other hereditary liver disease, drug-induced liver disease, etc. ); * Liver cirrhosis at clinical consideration or/and liver stiffness measurements (LSM) ≥ 12.4 kPa (for patients with ALT greater than the upper limit of normal, LSM ≥ 17.5 kPa); 27) Patients with clinically significant cardiac arrhythmias; history of risk factors for Torsade de Pointes (TdP) syndrome; * Uncontrolled hypertension with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening; * Patients with type I diabetes, or with newly diagnosed or poorly controlled type II diabetes (HbA1c \> 8.5%); * Left ventricular ejection fraction \< 50%.